59 results
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
14 May 24
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
4:12pm
the Company’s commitment to advancing it’s INM-901 program.
INM-089: Neuroprotection in the treatment of dry AMD
INM-089 is another proprietary small
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
18 Apr 24
Regulation FD Disclosure
1:30pm
in neurodegenerative disease to its Scientific Advisory Board (“SAB”) reinforcing the Company’s commitment to advancing it’s INM-901 program in the treatment
8-K
INM
InMed Pharmaceuticals Inc
18 Apr 24
Regulation FD Disclosure
1:30pm
Scientific Advisory Board (“SAB”) reinforcing the Company’s commitment to advancing it’s INM-901 program in the treatment of Alzheimer’s disease
8-K
EX-99.1
1sn61j 4nzt606xu751v
29 Sep 23
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
5:18pm
424B3
lcu4fr0tmdqzjscvhe
19 Oct 22
Prospectus supplement
6:10am
8-K
EX-99.1
nmo5vluf 06b
15 Jun 22
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential
6:04pm
8-K
q3ei9t33co3 8uttlxv0
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
8-K
EX-4.4
xsd 8ganrziweex
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
424B5
yns6c 61ljzo
3 Jun 22
Prospectus supplement for primary offering
9:45pm
8-K
EX-99.1
xat01excf5h
18 May 22
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
1:34pm
8-K
EX-99.1
gi4f02
6 May 22
Regulation FD Disclosure
2:50pm
8-K
EX-99.1
xcxq 9uyj0
28 Apr 22
Regulation FD Disclosure
2:35pm
8-K
EX-10.1
u9snay8k21x4d9p
7 Apr 22
Entry into a Material Definitive Agreement
4:47pm
424B3
oiz5uu
7 Apr 22
Prospectus supplement
4:46pm
8-K
EX-99.1
dcfqyz rs2fzo6z2
15 Feb 22
Regulation FD Disclosure
1:17pm